Oct 19, 2026 07:04AM
Oct 13, 2026 08:04AM
Sep 1, 2026 04:39PM
Aug 10, 2026 06:00AM
May 20, 2026 09:01AM
Mar 6, 2026 12:19PM
Mar 6, 2026 08:31AM H.C. Wainwright Reiterates Neutral Rating on aTyr Pharma (ATYR): "viewing the upcoming 1Q26 Type C meeting with the FDA as a critical catalyst"
Feb 3, 2026 08:01AM
Nov 6, 2025 04:02PM
Sep 15, 2025 04:23PM
Sep 15, 2025 01:42PM
Sep 15, 2025 12:55PM
Sep 15, 2025 12:23PM
Sep 15, 2025 11:57AM Leerink Partners Downgrades aTyr Pharma (ATYR) to Market Perform
Sep 15, 2025 11:57AM
Sep 15, 2025 10:58AM
Sep 15, 2025 07:26AM
Sep 12, 2025 06:38AM
Aug 22, 2025 05:30AM
Aug 4, 2025 06:59AM
Jul 29, 2025 10:55AM aTyr Pharma (ATYR) shorted by Shkreli
Jul 23, 2025 06:40AM
Jul 22, 2025 03:09PM
Jul 22, 2025 09:07AM
Jun 26, 2025 08:04AM
Jun 26, 2025 08:00AM
Jun 5, 2025 06:39AM
Jun 4, 2025 08:03AM aTyr Pharma (ATYR) Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease
May 14, 2025 08:02AM
May 7, 2025 04:04PM
Apr 23, 2025 09:43AM
Apr 21, 2025 06:47AM
Mar 26, 2025 08:01AM
Mar 17, 2025 07:06AM
Mar 14, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)
Mar 14, 2025 06:40AM
Mar 13, 2025 04:23PM
Mar 12, 2025 04:00PM
Mar 6, 2025 04:03PM
Feb 19, 2025 06:40AM
Jan 3, 2025 08:23AM
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 12, 2024 04:01PM
Dec 10, 2024 08:01AM
Nov 19, 2024 08:07AM
Oct 29, 2024 07:27AM
Oct 21, 2024 07:35AM
Oct 14, 2024 08:00AM
Oct 9, 2024 02:18PM Jones Trading Reiterates Buy Rating on aTyr Pharma (ATYR)
Oct 8, 2024 08:01AM

470,821 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All